Physician profile
Eric Larue
NPI 1902829708
$1,379.28
in general payments reported to CMS, 2019-2025
13 companies · $21.67 in 2025
The $21.67 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $135 · 2021: $469 · 2022: $392 · 2023: $162 · 2024: $55.24 · 2025: $21.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $403.28 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $324.04 | 2020-2022 | |
| Tris Pharma INC | $180.76 | 2022-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $116.40 | 2019-2020 | |
| Neos Therapeutics, Lp | $97.85 | 2021-2025 | Cotempla Xr-Odt |
| Corium, LLC | $78.99 | 2021-2023 | Azstarys |
| Pfizer INC. | $38.40 | 2020-2021 | |
| Aytu Biopharma, INC. | $34.37 | 2020-2024 | Karbinal |
| Glaxosmithkline, LLC. | $33.64 | 2019-2021 | |
| Shire North American Group INC | $19.80 | 2019 | |
| Sanofi Pasteur INC. | $18.39 | 2021 | |
| Vivus LLC | $18.22 | 2023 | Qsymia |
| Noven Therapeutics, LLC | $15.14 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Larue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.